专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08729334B2 Method for determining genotoxicity using non-fluorescent proteins 有权
标题翻译：使用非荧光蛋白测定遗传毒性的方法
公开(公告)号：US08729334B2
公开(公告)日：2014-05-20
申请号：US13578183
申请日：2011-03-31
申请人： Hyon El Choy , Seok-Yong Choi
发明人： Hyon El Choy , Seok-Yong Choi
IPC分类号： A61K49/00 , C12N15/12
CPC分类号： G01N33/5014 , A01K67/0275 , A01K2217/052 , A01K2227/40 , A01K2267/0393 , G01N33/5088
摘要： The present invention relates to a method for determining a genotoxicity of a test substance, comprising the steps of: (a) transforming a fish with a nucleotide sequence encoding a non-fluorescent fluorescence protein with a mutation; (b) treating a test substance to the transformed fish; and (c) measuring a fluorescence in the test substance-treated fish, wherein the fluorescence is generated by reversion of the non-fluorescent fluorescence protein to the fluorescence protein due to a back mutation of the nucleotide sequence in the test substance-treated fish. According to the present invention, MutaFish system, Zebrafish (Brachydanio rerio) line, in which the fluorescence protein variant, preferably wild type EGFP variant (EGFPmut) is transformed, provides a much excellent animal system for measuring a genotoxicity of a test substance via production of a fluorescent fry larvae generated through reversion of the fluorescent protein variant caused by treatment of the test substance. Accordingly, the MutaFish system of the present invention may determine a genotoxicity of a test substance in much more simple and high-throughput manner in an eukaryote to which the conventional methods (e.g., Ames test) may be not applied.
摘要翻译：本发明涉及测定物质的基因毒性的方法，其特征在于，包括以下步骤：（a）用编码具有突变的非荧光荧光蛋白的核苷酸序列转化鱼; （b）将经检测的物质处理至经转化的鱼; 和（c）测定被检物质处理过的鱼中的荧光，其中，由于检测物质处理的鱼中的核苷酸序列的反向突变，通过将非荧光荧光蛋白逆转为荧光蛋白而产生荧光。根据本发明，转化了荧光蛋白变体，优选野生型EGFP变体（EGFPmut）的MutaFish系统斑马鱼（Brachydanio rerio）系提供了非常优异的用于通过生产测量测试物质的基因毒性的动物系统通过由测试物质的处理引起的荧光蛋白质变体的逆转产生的荧光鱼苗。因此，本发明的MutaFish系统可以以更加简单和高通量的方式在常规方法（例如Ames测试）中不能应用的真核细胞中确定测试物质的基因毒性。

2. 发明申请

US20130024955A1 METHOD FOR DETERMINING GENOTOXICITY USING NON-FLUORESCENT PROTEINS 有权
标题翻译：使用非荧光蛋白测定细胞毒性的方法
公开(公告)号：US20130024955A1
公开(公告)日：2013-01-24
申请号：US13578183
申请日：2011-03-31
申请人： Hyon El Choy , Seok-Yong Choi
发明人： Hyon El Choy , Seok-Yong Choi
IPC分类号： A61K49/00 , C12N15/12
CPC分类号： G01N33/5014 , A01K67/0275 , A01K2217/052 , A01K2227/40 , A01K2267/0393 , G01N33/5088
摘要： The present invention relates to a method for determining a genotoxicity of a test substance, comprising the steps of: (a) transforming a fish with a nucleotide sequence encoding a non-fluorescent fluorescence protein with a mutation; (b) treating a test substance to the transformed fish; and (c) measuring a fluorescence in the test substance-treated fish, wherein the fluorescence is generated by reversion of the non-fluorescent fluorescence protein to the fluorescence protein due to a back mutation of the nucleotide sequence in the test substance-treated fish. According to the present invention, MutaFish system, Zebrafish (Brachydanio rerio) line, in which the fluorescence protein variant, preferably wild type EGFP variant (EGFPmut) is transformed, provides a much excellent animal system for measuring a genotoxicity of a test substance via production of a fluorescent fry larvae generated through reversion of the fluorescent protein variant caused by treatment of the test substance. Accordingly, the MutaFish system of the present invention may determine a genotoxicity of a test substance in much more simple and high-throughput manner in an eukaryote to which the conventional methods (e.g., Ames test) may be not applied.
摘要翻译：本发明涉及测定物质的基因毒性的方法，其特征在于，包括以下步骤：（a）用编码具有突变的非荧光荧光蛋白的核苷酸序列转化鱼; （b）将经检测的物质处理至经转化的鱼; 和（c）测定被检物质处理过的鱼中的荧光，其中，由于检测物质处理的鱼中的核苷酸序列的反向突变，通过将非荧光荧光蛋白逆转为荧光蛋白而产生荧光。根据本发明，其中荧光蛋白变体，优选野生型EGFP变体（EGFPmut）被转化的MutaFish系统斑马鱼（Brachydanio rerio）系提供了非常优异的用于通过生产测量测试物质的基因毒性的动物系统通过由测试物质的处理引起的荧光蛋白质变体的逆转产生的荧光鱼苗。因此，本发明的MutaFish系统可以以更加简单和高通量的方式在常规方法（例如Ames测试）中不能应用的真核细胞中确定测试物质的基因毒性。

3. 发明申请

US20120128594A1 SELECTIVE INFARCTED-TISSUE-TARGETING BACTERIA AND USE THEREOF 有权
标题翻译：选择性感染的组织 - 靶向细菌及其用途
公开(公告)号：US20120128594A1
公开(公告)日：2012-05-24
申请号：US13322637
申请日：2010-05-27
申请人： Hyon El Choy , Jung-Joon Min , Hyung Seok Kim , Yeongjin Hong
发明人： Hyon El Choy , Jung-Joon Min , Hyung Seok Kim , Yeongjin Hong
IPC分类号： A61K49/06 , A61P9/00 , A61K49/00 , A61P25/00 , A61K35/74 , A61K48/00
CPC分类号： A01K67/027 , A01K2207/12 , A01K2227/105 , A01K2267/0375 , A61K48/0033 , A61K2035/11 , C07K14/255 , C12N2830/001
摘要： The present invention relates to bacteria which specifically target infracted tissue and use thereof. The present invention provides a selective infracted tissue-targeting bacterium for the first time, and can be used in selectively delivering drugs to the infracted tissue or in selectively imaging the infracted tissue. The infracted tissue-targeting bacterium of the present invention can finish treatments by using antibiotics, and therefore, have remarkable advantages as compared to gene therapy using recombinant viruses. The infracted tissue-targeting bacterium of the present invention have a significantly high affinity and specificity to infracted myocardium or infracted brain, thereby significantly reducing undesired transfections in the organs or tissues other than the heart. The gene expression by the infracted tissue-targeting bacterium of the present invention in infracted myocardium or infracted brain is remotely controllable.
摘要翻译：本发明涉及特异性靶向不规则组织的细菌及其应用。本发明首次提供选择性致力于组织靶向的选择性细菌，并且可用于选择性地将药物递送至侵入组织或选择性地成像损伤的组织。本发明的致命组织靶向细菌可以通过使用抗生素来完成治疗，因此与使用重组病毒的基因治疗相比具有显着的优点。本发明的致伤组织靶向细菌对于心肌梗死或脑损伤具有显着高的亲和性和特异性，从而显着减少心脏以外的脏器或组织中的不期望的转染。本发明的致伤组织靶向细菌在减毒心肌或不规则脑中的基因表达是可远程控制的。

4. 发明授权

US09339018B2 Selective infarcted-tissue-targeting bacteria and use thereof 有权
标题翻译：选择性梗死组织靶向细菌及其用途
公开(公告)号：US09339018B2
公开(公告)日：2016-05-17
申请号：US13322637
申请日：2010-05-27
申请人： Hyon El Choy , Jung-Joon Min , Hyung Seok Kim , Yeongjin Hong
发明人： Hyon El Choy , Jung-Joon Min , Hyung Seok Kim , Yeongjin Hong
IPC分类号： A61K48/00 , A61K35/74 , A61K49/00 , A01K67/027 , C07K14/255 , A61K35/00
CPC分类号： A01K67/027 , A01K2207/12 , A01K2227/105 , A01K2267/0375 , A61K48/0033 , A61K2035/11 , C07K14/255 , C12N2830/001
摘要： The present invention relates to bacteria which specifically target infarcted tissue and use thereof. The present invention provides a selective infarcted tissue-targeting bacterium for the first time, and can be used in selectively delivering drugs to the infarcted tissue or in selectively imaging the infarcted tissue. The infarcted tissue-targeting bacterium of the present invention can finish treatments by using antibiotics, and therefore, have remarkable advantages as compared to gene therapy using recombinant viruses. The infarcted tissue-targeting bacterium of the present invention have a significantly high affinity and specificity to infarcted myocardium or infarcted brain, thereby significantly reducing undesired transfections in the organs or tissues other than the heart. The gene expression by the infarcted tissue-targeting bacterium of the present invention in infarcted myocardium or infarcted brain is remotely controllable.
摘要翻译：本发明涉及特异性靶向梗死组织的细菌及其应用。本发明首次提供了选择性梗塞的组织靶向细菌，并且可以用于选择性地将药物递送至梗死组织或选择性地成像梗塞组织。本发明的梗塞组织靶向细菌可以通过使用抗生素来完成治疗，因此与使用重组病毒的基因治疗相比具有显着的优点。本发明的梗死组织靶向细菌对梗塞的心肌或梗死的脑具有显着高的亲和性和特异性，从而显着减少心脏以外的器官或组织中不期望的转染。本发明的梗死组织靶向细菌在梗死心肌或梗死的脑中的基因表达是可远程控制的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式